Skip to main content
CivicGate

HRES 803
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

Introduced Oct 10, 2025

Latest action (Oct 10, 2025) Referred to the House Committee on Energy and Commerce.

Referred to
Energy and Commerce Committee
Policy area
Health
Issues
AbortionHealthcare

Summary

This resolution urges the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs, particularly in light of recent independent studies. The resolution also urges the FDA to publicly release a comprehensive safety review of chemical abortion drugs that includes real-world outcomes and complications data. The resolution provides background on prior expansions of access to chemical abortion drugs and recent FDA approval of a generic version of mifepristone.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
11 cosponsors

Actions (2)
  1. Oct 10, 2025 Referred to the House Committee on Energy and Commerce. · house
  2. Oct 10, 2025 Submitted in House

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • HRES 1285 — Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. · Introduced May 14, 2026 · Cong. 119 83%
  • SRES 732 — A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. · Introduced May 14, 2026 · Cong. 119 82%
  • HR 679 — To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes. · Introduced Jan 23, 2025 · Cong. 119 78%
  • S 1631 — Restoring Safeguards for Dangerous Abortion Drugs Act · Introduced May 6, 2025 · Cong. 119 76%
  • S 4066 — Safeguarding Women from Chemical Abortion Act · Introduced Mar 11, 2026 · Cong. 119 73%
  • HR 7902 — Safeguarding Women from Chemical Abortion Act · Introduced Mar 12, 2026 · Cong. 119 72%

Full text

IN THE HOUSE OF REPRESENTATIVES

October 10, 2025

Mr. Rose (for himself, Mrs. Harshbarger, Mr. Carter of Georgia, Mr. LaMalfa, Mrs. Biggs of South Carolina, Mr. Moore of Alabama, Ms. Hageman, and Mr. Grothman) submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

Whereas the Obama administration expanded access to chemical abortion drugs by removing in-person administration requirements, eliminating requirements for prescribers to report serious adverse effects, and removing follow- up care obligations; Whereas the Biden administration further expanded access to chemical abortion drugs by removing in-person dispensing requirements, permitting these drugs to be distributed by mail; Whereas the expansion of access to chemical abortion drugs has raised serious concerns regarding potential violations of Federal law, increased risks of coercion and domestic abuse, and even intentional misuse resulting in harm or death; Whereas chemical abortions now account for more than half of all abortions performed in the United States; Whereas many providers prescribing chemical abortion drugs receive taxpayer funding, raising ethical and legal concerns regarding the use of public funds; Whereas, on September 30, 2025, the Food and Drug Administration approved a new generic version of mifepristone, further expanding the availability of chemical abortion drugs; Whereas this approval will likely contribute to a significant increase in the number of unborn children lost to abortion, and poses a risk of potential physical and emotional harm to women and girls, while undermining pro-life laws enacted by numerous States; and Whereas independent research suggests that chemical abortions carry a rate of serious complications that is 22 times higher than what is currently reported by the Food and Drug Administration and drug manufacturers: Now, therefore, be it Resolved, That the House of Representatives urges the Director of the Food and Drug Administration—

(1) to reevaluate the safety of all chemical abortion drugs in light of recent independent studies; and

(2) to publicly release a full safety review of such drugs that includes real-world outcomes and complications. <all>

Comments

Comments

Loading comments…